close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Michael Carducci

LOCATION OF PRACTICE
Johns Hopkins University School Of Medicine
MEDICAL Specialty:

Baltimore Md, Prostate Cancer



NPI Number
1952369977
ABOUT

Michael A. Carducci, MD is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology.

Dr. Michael Carducci profile image

Published Articles

Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).- 2026 Apr 10
Leveraging MrkA Display on Self-Assembling Protein Nanoparticles for Enhanced Immune Activation.- 2026 Apr 9
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).- 2026 Mar 15
Smoothness and stability in the Alt-Phillips problem.- 2026
Age- and Treatment-Related Patterns in Fatigue, Coping/Resilience, and Skeletal Muscle Bioenergetics ((31)P-MRS τPCr) in Cancer Survivors: Exploratory Pilot Analysis.- 2026 Feb 17
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.- 2026 Feb 26
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).- 2026 Feb 18
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing.- 2026 Feb 19
A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.- 2026 Mar 9
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).- 2026 May

Clinical Trials

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy
Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Simultaneous Care: Linking Palliation to Clinical Trials
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

My Patient Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider